Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals) Company Analysis & Research
Mallinckrodt completed the spin-off of Par Health and rebranded as Keenova Therapeutics, focusing on developing and commercializing branded therapeutics for patients with rare or unaddressed conditions. The company reported pro-forma 2024 revenue of $1.7B with 1,600 employees and is headquartered in Dublin.
Key products include Acthar Gel for inflammatory/autoimmune conditions and XIAFLEX for Dupuytren's contracture and Peyronie's disease. Keenova intends to pursue a NYSE listing in 2026.
Company Overview
Founded: 1867. Headquarters: Dublin, Ireland. Revenue: $1.7B. Employees: 1,600. Market Cap: $4.5M. Ticker: MNK (NASDAQ).
Industry
Specialty Pharmaceuticals - Rare & Orphan Diseases
Cyborg Score: 5/10 — Mixed
Keenova represents a turnaround story with established products in growing rare disease markets, but faces execution risk and market skepticism reflected in valuation.
Company emerged from bankruptcy restructuring in 2023 and completed a transformational merger and spin-off, establishing clear strategic focus on branded therapeutics. However, extremely depressed market capitalization and recent capital structure constraints indicate investor concerns regarding execution and market positioning.
Key Strategic Insights for Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)
- November 2025: Completed Par Health spin-off, transforming from diversified generics-branded company to pure-play rare disease specialist
- February 2026: Presented Phase 2 extension data on collagenase for plantar fibromatosis with Phase 3 trial expected to deliver topline results mid-2026
- Recent focus on terlipressin (TERLIVAZ), first FDA-approved therapy for hepatorenal syndrome kidney function improvement
- Market cap severely depressed at $4.5M (Jan 2026) despite $1.7B revenue, suggesting significant market skepticism or delisting risk
Recent Developments
- (February 2026) Presented Phase 2 plantar fibromatosis data at ACFAS Annual Meeting; Phase 3 results expected mid-2026
- (November 2025) Completed Par Health spin-off and rebranded as Keenova Therapeutics
- (August 2025) Completed merger with Endo, Inc. to create scaled diversified therapeutics leader
Competitors & Competitive Landscape
- AstraZeneca/Alexion — Complement inhibitors for autoimmune conditions
- Horizon Therapeutics — IGF-1 receptor inhibitor for thyroid eye disease
- Ultragenyx — Rare metabolic and genetic disease treatments
Keenova competes in autoimmune and rare diseases across neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology. Key competitors include other rare disease specialists like Alexion (AstraZeneca subsidiary), Horizon Therapeutics, and Ultragenyx, as well as larger pharma companies with rare disease portfolios.
More Company Research
Rocket Pharmaceuticals, Inc. Solocal Group Noevir Holdings Co., Ltd. Alexander & Baldwin, Inc. PENN Entertainment, Inc. Centerra Gold Inc. Atlassian Corporation Adani Total Gas Limited Norwegian Cruise Line Holdings Ltd. Zangge Mining Company Limited Roblox Corporation PainReform Fire Rock Fujairah Building Industries P.J.S.C. Eurocash S.A.Full Company Research Reports
Looking for a more in-depth analysis of Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.